QURE (uniQure N.V.)
Insider Trading Activity
Every open-market purchase and sale reported by QURE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | Matthew C Kapusta | CEO, Managing Director | MIXED | — | — |
| 2026-07-02 | Jack Kaye | Director | MIXED | — | — |
| 2026-07-02 | Walid Abi-Saab | Chief Medical Officer | MIXED | — | — |
| 2026-06-26 | Matthew C Kapusta | CEO, Managing Director | MIXED | — | — |
| 2026-06-22 | Madhavan Balachandran | Director | MIXED | — | — |
| 2026-06-22 | Matthew C Kapusta | CEO, Managing Director | MIXED | — | — |
| 2026-06-22 | Jack Kaye | Director | MIXED | — | — |
| 2026-06-17 | Jeannette Potts | Chief Legal Officer | Sell | — | — |
| 2026-06-17 | Madhavan Balachandran | Director | MIXED | — | — |
| 2026-06-12 | Kylie O'Keefe | Chief Customer & Strat Officer | Sell | — | — |
| 2026-06-12 | Rachelle Suzanne Jacques | Director | MIXED | — | — |
| 2026-06-12 | Jack Kaye | Director | MIXED | — | — |
| 2026-06-12 | LEONARD E POST | Director | MIXED | — | — |
| 2026-06-12 | David D. Meek | Director | MIXED | — | — |
| 2026-06-12 | Robert Gut | Director | MIXED | — | — |
| 2026-06-12 | Jeremy P. Springhorn | Director | MIXED | — | — |
| 2026-06-12 | Madhavan Balachandran | Director | MIXED | — | — |
| 2026-06-05 | Jack Kaye | Director | MIXED | — | — |
| 2026-05-12 | Walid Abi-Saab | Chief Medical Officer | MIXED | — | — |
| 2026-03-09 | Kylie O'Keefe | Chief Customer & Strat Officer | A | — | — |
| 2026-03-06 | Matthew C Kapusta | CEO, Managing Director | MIXED | — | — |
| 2026-03-06 | CHRISTIAN KLEMT | Chief Financial Officer | MIXED | — | — |
| 2026-03-06 | Jeannette Potts | Chief Legal Officer | MIXED | — | — |
| 2026-03-06 | Walid Abi-Saab | Chief Medical Officer | MIXED | — | — |
| 2026-03-04 | Walid Abi-Saab | Chief Medical Officer | Sell | — | — |
| 2026-03-04 | CHRISTIAN KLEMT | Chief Financial Officer | Sell | — | — |
| 2026-03-04 | Matthew C Kapusta | CEO, Managing Director | Sell | — | — |
| 2026-03-04 | Jeannette Potts | Chief Legal Officer | Sell | — | — |
| 2026-02-27 | CHRISTIAN KLEMT | Chief Financial Officer | Sell | — | — |
| 2026-02-27 | Matthew C Kapusta | CEO, Managing Director | Sell | — | — |
| 2026-01-14 | Robert Gut | Director | MIXED | — | — |
| 2026-01-12 | Jack Kaye | Director | MIXED | — | — |
| 2025-11-10 | Robert Gut | Director | MIXED | — | — |
| 2025-11-06 | Jack Kaye | Director | MIXED | — | — |
| 2025-09-26 | CHRISTIAN KLEMT | Chief Financial Officer | MIXED | — | — |
| 2025-09-26 | Matthew C Kapusta | CEO, Managing Director | MIXED | — | — |
| 2025-07-01 | Walid Abi-Saab | Chief Medical Officer | Sell | — | — |
| 2025-06-24 | LEONARD E POST | Director | Sell | — | — |
| 2025-06-24 | Madhavan Balachandran | Director | Sell | — | — |
| 2025-06-24 | David D. Meek | Director | Sell | — | — |
| 2025-06-24 | Jack Kaye | Director | Sell | — | — |
| 2025-06-24 | Rachelle Suzanne Jacques | Director | Sell | — | — |
| 2025-06-24 | Robert Gut | Director | Sell | — | — |
| 2025-06-24 | Jeremy P. Springhorn | Director | Sell | — | — |
| 2025-06-20 | Jeannette Potts | Chief Legal Officer | Sell | — | — |
| 2025-06-13 | Madhavan Balachandran | Director | A | — | — |
| 2025-06-13 | David D. Meek | Director | A | — | — |
| 2025-06-13 | Jack Kaye | Director | A | — | — |
| 2025-06-13 | LEONARD E POST | Director | A | — | — |
| 2025-06-13 | Robert Gut | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO, Managing Director | 519,227 | — |
| — | Chief Financial Officer | 226,581 | — |
| — | Chief Medical Officer | 178,235 | — |
| — | President, R&D | 163,404 | — |
| — | Chief Medical Officer | 159,458 | — |
| — | Chief Legal Officer | 133,246 | — |
| — | Chief Operating Officer | 115,707 | — |
| — | Chief Customer & Strat Officer | 108,864 | — |
| — | Chief Commercial Officer | 93,817 | — |
| — | Chief Business Officer | 93,638 | — |
| — | SVP, Investor Rel. & Comm. | 92,439 | — |
| — | Executive VP, Operations | 90,381 | — |
| — | EVP, Research & Product Dev. | 71,458 | — |
| — | Director | 46,978 | — |
| — | Director | 43,254 | — |
| — | Director | 43,251 | — |
| — | Director | 43,056 | — |
| — | Director | 41,740 | — |
| — | Director | 35,896 | — |
| — | Director | 35,494 | — |
| — | Director | 32,342 | — |
| — | Chief Scientific Officer | 21,547 | — |
| — | Chief Operating Officer | 20,432 | — |
| — | Director | 20,203 | — |
| — | Director | 9,946 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QURE quote page; the site-wide leaderboard is on the insider transactions hub.